Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

73.69 +9.20 (+14.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
PTC Therapeutics Q1 Earnings Call Highlights ↗
PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or... 
Via MarketBeat
Topics Earnings
News headline image
PTCT Q1 2026 Earnings Transcript ↗
PTCT Q1 2026 Earnings Transcript 
Via The Motley Fool
PTC Therapeutics Inc (NASDAQ:PTCT) Delivers Q1 Earnings Beat and Raises 2026 Guidance ↗
Via Chartmill
Topics Earnings
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
PTC Therapeutics Inc (NASDAQ:PTCT) Stock Slides After Q4 Earnings Miss ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation ↗
Via Chartmill
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates. 
Via The Motley Fool
Topics Regulatory Compliance
PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup ↗
Via Chartmill
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets. 
Via The Motley Fool
Topics Regulatory Compliance
PTC Therapeutics Inc (NASDAQ:PTCT): A Prime Candidate for Affordable Growth Investing ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows High-Growth Momentum and Bullish Technical Setup ↗
PTC Therapeutics stock shows strong earnings momentum and a top-rated technical setup, offering a potential breakout opportunity for growth investors. 
Via Chartmill
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? ↗
Via The Motley Fool
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
PTC Therapeutics (PTCT) exemplifies a strong growth stock with a bullish technical setup, combining high sales growth, robust margins, and a potential chart breakout. 
Via Chartmill
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Reasonable Valuation ↗
PTC Therapeutics offers high growth at a fair price, with strong earnings and revenue increases, trading below industry valuations. 
Via Chartmill
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
Via The Motley Fool
News headline image
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 ↗
Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
PTC Therapeutics offers strong growth and solid financials at a fair price, making it an attractive stock for investors seeking affordable expansion opportunities. 
Via Chartmill
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows Strong Growth Momentum and Technical Health ↗
PTC Therapeutics (PTCT) shows explosive earnings growth of 277% and strong technicals, presenting a high-momentum investment opportunity. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.